alveolar soft part sarcoma
alveolar soft part sarcoma
Explore linked clinical trials. Standard reference: MONDO:001165515 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Testing Atezolizumab Alone or Atezolizumab Plus Bevacizumab in People With Advanced Alveolar Soft Part Sarcoma | Neoplasms by Histologic Type, Neoplasms, Connective and Soft Tissue, alveolar soft part sarcoma, myomatous neoplasm, neoplasm, sarcoma | Active, not recruiting | Phase 2 | 2026-10-09 | NCT03141684 | |
| GCAR1, a Chimeric Antigen Receptor (CAR) T-CELL Therapy for Relapsed/Refractory GPNMB-Expressing Solid Tumours | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Connective and Soft Tissue, Skin and Connective Tissue Diseases, Urogenital Diseases, Urogenital Neoplasms, adenocarcinoma, alveolar soft part sarcoma, benign urinary system neoplasm, breast disorder, breast neoplasm, carcinoma, epithelial neoplasm, kidney cancer, kidney disorder, myomatous neoplasm, neoplasm, renal cell carcinoma, sarcoma, skin disorder, triple-negative breast carcinoma, urinary system disorder | Recruiting | Phase 1 | 2026-10-08 | NCT07297667 | |
| A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing | Digestive System Diseases, Digestive System Neoplasms, Liver Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Connective and Soft Tissue, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Skin and Connective Tissue Diseases, Thoracic Neoplasms, adenocarcinoma, alveolar soft part sarcoma, bronchial neoplasm, bronchogenic carcinoma, carcinoma, epithelial neoplasm, hepatocellular carcinoma, liver disorder, lung disorder, lung neoplasm, melanocytic neoplasm, melanoma, metastatic melanoma, myomatous neoplasm, neoplasm, neuroendocrine neoplasm, non-small cell lung carcinoma, primitive neuroectodermal tumor, respiratory system disorder, respiratory tract neoplasm, sarcoma, skin disorder, skin neoplasm, small cell lung carcinoma | Recruiting | Phase 1 | 2026-10-08 | NCT06066138 | |
| Testing Atezolizumab With Selinexor in People ≥ 12 Years Old With Alveolar Soft Part Sarcoma, AXIOM Trial | Neoplasms by Histologic Type, Neoplasms, Connective and Soft Tissue, alveolar soft part sarcoma, myomatous neoplasm, neoplasm, sarcoma | Recruiting | Phase 2 | 2026-10-02 | NCT05333458 | |
| Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors | Carcinoma, Medullary, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Digestive System Diseases, Digestive System Neoplasms, Ewing sarcoma, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Liver Neoplasms, Male Urogenital Diseases, Myosarcoma, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Bone Tissue, Neoplasms, Connective and Soft Tissue, Neoplasms, Ductal, Lobular, and Medullary, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Urogenital Diseases, Urogenital Neoplasms, Wilms tumor, adenocarcinoma, adrenal cortex disorder, adrenal cortex neoplasm, adrenal gland cancer, adrenal gland disorder, alveolar soft part sarcoma, benign urinary system neoplasm, carcinoma, central nervous system cancer, clear cell sarcoma, connective tissue neoplasm, endocrine system disorder, epithelial neoplasm, hepatoblastoma, hepatocellular carcinoma, hereditary disease, hereditary neoplastic syndrome, kidney cancer, kidney disorder, liver disorder, malignant endocrine neoplasm, medullary thyroid gland carcinoma, mixed neoplasm, myomatous neoplasm, neoplasm, nervous system disorder, neuroendocrine carcinoma, neuroendocrine neoplasm, osteosarcoma, primitive neuroectodermal tumor, renal cell carcinoma, rhabdomyosarcoma, sarcoma, urinary system disorder | Active, not recruiting | Phase 2 | 2026-08-28 | NCT02867592 | |
| AB122 Platform Study | Biliary Tract Neoplasms, Digestive System Diseases, Digestive System Neoplasms, Esophageal Neoplasms, Head and Neck Neoplasms, Neoplasm Metastasis, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Connective and Soft Tissue, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Thoracic Neoplasms, alveolar soft part sarcoma, biliary tract cancer, biliary tract disorder, bronchial neoplasm, bronchogenic carcinoma, colonic disorder, colorectal cancer, colorectal neoplasm, digestive system disorder, digestive system neoplasm, esophageal cancer, esophageal disorder, gastric cancer, gastric neoplasm, head and neck cancer, intestinal disorder, lung disorder, lung neoplasm, myomatous neoplasm, neoplasm, non-small cell lung carcinoma, pancreatic ductal adenocarcinoma, rectal disorder, respiratory system disorder, respiratory tract neoplasm, sarcoma, stomach disorder | Recruiting | Phase 1 | 2026-08-05 | NCT04999761 | |
| A Study to Determine the Safety and Effectiveness of the Investigational Cellular Therapy GCAR1 in a Patient With Alveolar Soft Part Sarcoma | Neoplasms by Histologic Type, Neoplasms, Connective and Soft Tissue, alveolar soft part sarcoma, myomatous neoplasm, neoplasm, sarcoma | Active, not recruiting | Early phase 1 | 2026-08-04 | NCT07104682 | |
| Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Ewing sarcoma, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Myosarcoma, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Bone Tissue, Neoplasms, Connective and Soft Tissue, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Neuroectodermal Tumors, Primitive, Neuroectodermal Tumors, Primitive, Peripheral, Peripheral Nerve Sheath Tumors, Urogenital Diseases, Urogenital Neoplasms, Wilms tumor, alveolar soft part sarcoma, benign urinary system neoplasm, chordoma, clear cell sarcoma, connective tissue neoplasm, desmoplastic small round cell tumor, epithelial neoplasm, hereditary disease, hereditary neoplastic syndrome, kidney cancer, kidney disorder, mixed neoplasm, myoepithelial tumor, myomatous neoplasm, neoplasm, nerve sheath neoplasm, nervous system disorder, neuroblastoma, neuroepithelial neoplasm, neuromuscular disease, osteosarcoma, peripheral nervous system disorder, peripheral nervous system neoplasm, primitive neuroectodermal tumor, rhabdoid tumor, rhabdomyosarcoma, sarcoma, synovial sarcoma, urinary system disorder | Recruiting | Phase 1 / Phase 2 | 2026-06-30 | NCT06625190 | |
| Clinical Trials of Benmelstobart Injection Combined With Anlotinib Hydrochloride Capsules in the Treatment of Advanced or Unresectable Alveolar Soft Part Sarcoma | Neoplasms by Histologic Type, Neoplasms, Connective and Soft Tissue, alveolar soft part sarcoma, myomatous neoplasm, neoplasm, sarcoma | Recruiting | Phase 2 | 2026-04-23 | NCT07548177 | |
| A Study of Pembrolizumab Plus Local Chemotherapy Using Isolated Limb Infusion (ILI) for Patients With Sarcoma in the Arm or Leg | Neoplasms by Histologic Type, Neoplasms, Connective and Soft Tissue, Neoplasms, Fibrous Tissue, alveolar soft part sarcoma, connective tissue neoplasm, dermatofibrosarcoma protuberans, fibrosarcoma, histiocytoma, myomatous neoplasm, myxofibrosarcoma, neoplasm, sarcoma, undifferentiated pleomorphic sarcoma | Recruiting | Phase 2 | 2026-04-23 | NCT04332874 | |
| GPNMB-targeting Chimeric Antigen Receptor T-Cell Therapy (GCAR1) for a Patient With Alveolar Soft Part Sarcoma (CLIC-YYC-GPNMB-02) | Neoplasms by Histologic Type, Neoplasms, Connective and Soft Tissue, alveolar soft part sarcoma, myomatous neoplasm, neoplasm, sarcoma | Active, not recruiting | Early phase 1 | 2026-03-23 | NCT06789081 | |
| Phase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma (APROMISS) | Neoplasms by Histologic Type, Neoplasms, Connective and Soft Tissue, alveolar soft part sarcoma, connective tissue neoplasm, leiomyosarcoma, myomatous neoplasm, neoplasm, sarcoma, synovial sarcoma | Recruiting | Phase 3 | 2026-02-25 | NCT03016819 | |
| Multimodal Immune Characterization of RAre Soft Tissue Sarcoma - MIRAS Project From SARRA (SARcome RAre) Project of the French Sarcoma Group | Neoplasms by Histologic Type, Neoplasms, Connective and Soft Tissue, alveolar soft part sarcoma, clear cell sarcoma, connective tissue neoplasm, desmoplastic small round cell tumor, epithelioid hemangioendothelioma, hemangioendothelioma, hemangioma, low grade fibromyxoid sarcoma, myomatous neoplasm, neoplasm, neoplasm with perivascular epithelioid cell differentiation, sarcoma, vascular cancer | Recruiting | Not applicable | 2026-02-10 | NCT03967834 | |
| CAR T Therapy With GCAR1 for Relapsed Alveolar Soft Part Sarcoma | Neoplasms by Histologic Type, Neoplasms, Connective and Soft Tissue, alveolar soft part sarcoma, myomatous neoplasm, neoplasm, sarcoma | Active, not recruiting | Early phase 1 | 2025-04-10 | NCT06813417 | |
| Evaluation of Chest CT Versus Chest X-Ray for Lung Surveillance After Curative-Intent Resection of High-Risk Truncal-Extremity Soft Tissue Sarcoma | Metastatic Dermatofibrosarcoma Protuberans, Neoplasms by Histologic Type, Neoplasms, Adipose Tissue, Neoplasms, Connective and Soft Tissue, Neoplasms, Fibrous Tissue, Neoplasms, Nerve Tissue, adult pleomorphic rhabdomyosarcoma, alveolar soft part sarcoma, angiosarcoma, clear cell sarcoma, connective tissue neoplasm, dermatofibrosarcoma protuberans, extraskeletal Ewing sarcoma, extraskeletal myxoid chondrosarcoma, fibrosarcoma, histiocytoma, leiomyosarcoma, liposarcoma, myomatous neoplasm, myxofibrosarcoma, neoplasm, nerve sheath neoplasm, nervous system disorder, neurofibroma, neurofibrosarcoma, neuromuscular disease, peripheral nervous system disorder, peripheral nervous system neoplasm, round cell sarcoma with EWSR1-non-ETS fusion, sarcoma, synovial sarcoma, undifferentiated pleomorphic sarcoma, vascular cancer | Not yet recruiting | Not applicable | 2024-07-30 | NCT06526897 |